[ad_1]
The antibody drug developed by Eli Lilly & Co. received emergency use authorization from US regulators for the treatment of mild and moderate cases of COVID-19, writes Mediafax.
Following this decision, access to a treatment that, according to the data, is effective in keeping people infected with coronavirus out of the hospital is expanding.
The Food and Drug Administration has licensed the experimental treatment, called Bamlanivimab, for use of the drug against mild to moderate forms of COVID-19, including those 65 and older and pediatric patients, writes Bloomberg citing the website of the pharmaceutical company. .
Florin Cîţu is more than OPTIMIST: We have a recovery of the economy in V and the unemployment rate has dropped
The authorization gives doctors the option to address the virus in high-risk patients before they are sick enough to require hospitalization.
Other FDA-approved treatments, such as Gilead Sciences Inc.’s convalescent plasma and antiviral remdesivir, are designed for use in critically ill COVID-19 patients.
Now begins an even more difficult challenge: the distribution of the drug. The pharmaceutical company said that bamlanivimab should be administered “as soon as possible after a positive COVID-19 test and within 10 days of the onset of symptoms.”
Lilly will immediately begin delivering the antibody to AmerisourceBergen Corp., which will distribute it in accordance with instructions from the US government. Americans will pay nothing for the drug, the company said.
[ad_2]
